CD274 and head and neck squamous cell carcinoma: PD-L1 status was the first validated biomarker of efficacy to identify patients most likely to derive a benefit from pembrolizumab either as a stand-alone agent16 or in combination with chemotherapy, for example, in advanced HNSCC and cervical cancer11,12.